Reports have indicated that the administration of JAK-STAT inhibitors, notably tofacitinib and ruxolitinib, has resulted in favorable clinical outcomes for the treatment of sarcoidosis, as evidenced by multiple case reports, open-label clinical trials, and observational studies [174]. Here, SOAT1 is linked to sarcoidosis.